



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 20 Jun 2022 (#24)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-CA-22-093](#) **Notice to Extend Expiration Date for [PAR-20-277](#)**: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed). New Expiration Date: January 08, 2023.

[NOT-TW-22-004](#) **Notice of Change to PD(s)/PI(s) Eligibility Requirements and Addition of Letter of Intent Deadline for [PAR-19-362](#) Planning Grant for Global Infectious Disease Research Training Program (D71 - Clinical Trials Not Allowed)**. The PD/PI from the LMIC applicant institution must not be a current or former PD/PI of a FIC research training grants (D43 or U2R awards). Letter of Intent Due Date: September 28, 2022.

[NOT-CA-22-094](#) **Notice of Intent to Publish a Funding Opportunity Announcement for NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)**. The National Cancer Institute (NCI) intends to reissue the NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) Funding Opportunity Announcement (FOA), which supports preclinical and early-phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer disparities. First Estimated Application Due Date: October 20, 2022

Notice of Special Interest (NOSI)

[NOT-HD-22-016](#) **NOSI: Research to Support Regulatory Science on Infant Formula**. The purpose of this NOSI is to invite investigator-initiated applications addressing major research gaps in the evidence base to support regulation of biologically active substances, components and molecules that are intended for use in infant formula. Human milk research has brought to the attention of researchers, infant formula companies and families alike the possibility that new biologically active (bioactive) substances found in human milk could be added to infant formula as ingredients

to improve child health. While research on the function and safety of most of these bioactive substances is scarce, the FDA is still required to make decisions on whether these ingredients can be included in infant formulas in a timely fashion. This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through May 8, 2023.

[NOT-OD-22-154](#) Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities. The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities. This NOSI focuses specifically on preventive interventions addressing cardiometabolic risk factors across the lifespan in populations that experience health disparities. Efforts to improve these risk factors should be based on research that identifies and addresses relevant determinants of health at individual, interpersonal, organizational, community, and societal levels. As part of proposed prevention interventions, investigators should work in collaboration with appropriate community, service system, and/or healthcare partners to develop and evaluate interventions that are relevant, acceptable, and sustainable in community and service settings. Proposed projects must include an intervention that addresses at least one cardiometabolic risk factor, alone or in combination with other types of risk factors (e.g., smoking, occupational risks), in one or more populations that experience health disparities. This notice applies to due dates on or after October 5, 2022 and subsequent receipt dates through September 8, 2025.

Funding Opportunity Announcements (FOA)

1. Precision Approaches in Radiation Synthetic Combinations (PAIRS) (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-198](#)

Type: R01

Application Due Date: October 05, 2022 through to June 05, 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this FOA, the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

2. Precision Approaches in Radiation Synthetic Combinations (PAIRS) (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-199](#)

Type: R21

Application Due Date: October 16, 2022 through to June 16, 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

3. Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-23-011](#)

Type: UM1

Application Due Date: November 15, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institute on Drug Abuse (NIDA) seeks applications to develop and maintain a medicinal cannabis use registry to assess the medical conditions reported as reasons for using medicinal cannabis, how and what products are being used, and the associated medical outcomes. The goal of this registry is to inform research, policy, and clinical recommendation practices on medicinal cannabis, associated conditions, and outcomes.

Budget: NIDA intends to commit \$1,500,000 in direct costs in FY 2023 to fund one award. Application budgets are limited to \$1,500,000 in direct costs for FY23. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: [Christa](#)
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: [Lizél](#)
e: lizelk@sun.ac.za | t: +27 21 808 2105